|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q60327268
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010851.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q60327268
|
|
024
|
|
|
‡a
0000-0002-2252-4636
‡2
orcid
|
|
024
|
|
|
‡a
23982451800
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q60327268
|
|
100
|
0 |
|
‡a
Louisa K James
‡9
es
‡9
ast
|
|
400
|
0 |
|
‡a
লুইসা কে জেমস
‡9
bn
|
|
400
|
0 |
|
‡a
Louisa K James
‡c
researcher ORCID ID = 0000-0002-2252-4636
‡9
en
|
|
400
|
0 |
|
‡a
Louisa K James
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's A Phl p 7-specific IgG4 antibody inhibits allergic patients IgE cross-reactivity to allergens from the EF-hand family: importance of affinity and degree of cross-reactivity
|
|
670
|
|
|
‡a
Author's A tool kit for rapid cloning and expression of recombinant antibodies
|
|
670
|
|
|
‡a
Author's Allergen specificity of IgG4-expressing B cells in patients with grass pollen allergy undergoing immunotherapy
|
|
670
|
|
|
‡a
Author's Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps
|
|
670
|
|
|
‡a
Author's Cell2location maps fine-grained cell types in spatial transcriptomics
|
|
670
|
|
|
‡a
Author's Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
|
|
670
|
|
|
‡a
Author's Cross-tissue immune cell analysis reveals tissue-specific adaptations and clonal architecture across the human body
|
|
670
|
|
|
‡a
Author's Cross-tissue immune cell analysis reveals tissue-specific features in humans
|
|
670
|
|
|
‡a
Author's Distinct microbial and immune niches of the human colon
|
|
670
|
|
|
‡a
Author's Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps
|
|
670
|
|
|
‡a
Author's Epitope specificity determines cross-protection of a SIT-induced IgG4 antibody
|
|
670
|
|
|
‡a
Author's Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression
|
|
670
|
|
|
‡a
Author's Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
|
|
670
|
|
|
‡a
Author's IgE binds asymmetrically to its B cell receptor CD23
|
|
670
|
|
|
‡a
Author's IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens
|
|
670
|
|
|
‡a
Author's Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis
|
|
670
|
|
|
‡a
Author's Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class
|
|
670
|
|
|
‡a
Author's Interplay between Affinity and Valency in Effector Cell Degranulation: A Model System with Polcalcin Allergens and Human Patient-Derived IgE Antibodies
|
|
670
|
|
|
‡a
Author's Isolation and Characterization of Lymphocytes from Human Mucosal Biopsies
|
|
670
|
|
|
‡a
Author's Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies
|
|
670
|
|
|
‡a
Author's Orchestration of immunoglobulin isotypes, subclasses, and specificities in patients receiving intravenous IgG or subcutaneous immunotherapy and those with chronic rhinosinusitis with nasal polyps: Toward precision medicine
|
|
670
|
|
|
‡a
Author's Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions
|
|
670
|
|
|
‡a
Author's Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.
|
|
670
|
|
|
‡a
Author's Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes
|
|
670
|
|
|
‡a
Author's Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE?
|
|
670
|
|
|
‡a
Author's Serum immunologic markers for monitoring allergen-specific immunotherapy
|
|
670
|
|
|
‡a
Author's Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition
|
|
670
|
|
|
‡a
Author's The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy
|
|
909
|
|
|
‡a
(orcid) 0000000222524636
‡9
1
|
|
909
|
|
|
‡a
(scopus) 23982451800
‡9
1
|
|
919
|
|
|
‡a
dupilumabclinicalefficacyofblockingil4il13signallinginchronicrhinosinusitiswithnasalpolyps
‡A
Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps
‡9
1
|
|
919
|
|
|
‡a
distinctmicrobialandimmunenichesofthehumancolon
‡A
Distinct microbial and immune niches of the human colon
‡9
1
|
|
919
|
|
|
‡a
crosstissueimmunecellanalysisrevealstissuespecificfeaturesinhumans
‡A
Cross-tissue immune cell analysis reveals tissue-specific features in humans
‡9
1
|
|
919
|
|
|
‡a
cloningandexpressionofhumanmonoclonalantibodiesimplicationsforallergenimmunotherapy
‡A
The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy
‡9
1
|
|
919
|
|
|
‡a
structureofapatientderivedantibodyincomplexwithallergenrevealssimultaneousconventionalandsuperantigenlikerecognition
‡A
Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition
‡9
1
|
|
919
|
|
|
‡a
serumimmunologicmarkersformonitoringallergenspecificimmunotherapy
‡A
Serum immunologic markers for monitoring allergen-specific immunotherapy
‡9
1
|
|
919
|
|
|
‡a
rhinitiswithnegativeskintestsandabsentserumallergenspecificigemoreevidenceforlocalige
‡A
Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE?
‡9
1
|
|
919
|
|
|
‡a
protocolforarandomiseddoubleblindplacebocontrolledstudyofgrassallergenimmunotherapytabletforseasonalallergicrhinitistimecourseofnasalcutaneousandimmunologicaloutcomes
‡A
Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes
‡9
1
|
|
919
|
|
|
‡a
proinsulinpeptideimmunotherapyintype1diabetesreportofa1inmanphase1safetystudy
‡A
Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.
‡9
1
|
|
919
|
|
|
‡a
potentialmechanismsforigg4inhibitionofimmediatehypersensitivityreactions
‡A
Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions
‡9
1
|
|
919
|
|
|
‡a
orchestrationofimmunoglobulinisotypessubclassesandspecificitiesinpatientsreceivingintravenousiggorsubcutaneousimmunotherapyandthosewithchronicrhinosinusitiswithnasalpolypstowardprecisionmedicine
‡A
Orchestration of immunoglobulin isotypes, subclasses, and specificities in patients receiving intravenous IgG or subcutaneous immunotherapy and those with chronic rhinosinusitis with nasal polyps: Toward precision medicine
‡9
1
|
|
919
|
|
|
‡a
longtermtoleranceafterallergenimmunotherapyisaccompaniedbyselectivepersistenceofblockingantibodies
‡A
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies
‡9
1
|
|
919
|
|
|
‡a
isolationandcharacterizationoflymphocytesfromhumanmucosalbiopsies
‡A
Isolation and Characterization of Lymphocytes from Human Mucosal Biopsies
‡9
1
|
|
919
|
|
|
‡a
interplaybetweenaffinityandvalencyineffectorcelldegranulationamodelsystemwithpolcalcinallergensandhumanpatientderivedigeantibodies
‡A
Interplay between Affinity and Valency in Effector Cell Degranulation: A Model System with Polcalcin Allergens and Human Patient-Derived IgE Antibodies
‡9
1
|
|
919
|
|
|
‡a
inhibitionofallergendependentigeactivitybyantibodiesofthesamespecificitybutdifferentclass
‡A
Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class
‡9
1
|
|
919
|
|
|
‡a
influenceofseasonalexposuretograsspollenonlocalandperipheralbloodigerepertoiresinpatientswithallergicrhinitis
‡A
Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis
‡9
1
|
|
919
|
|
|
‡a
igg4inhibitspeanutinducedbasophilandmastcellactivationinpeanuttolerantchildrensensitizedtopeanutmajorallergens
‡A
IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens
‡9
1
|
|
919
|
|
|
‡a
igebindsasymmetricallytoitsbcellreceptorcd23
‡A
IgE binds asymmetrically to its B cell receptor CD23
‡9
1
|
|
919
|
|
|
‡a
phlp7specificigg4antibodyinhibitsallergicpatientsigecrossreactivitytoallergensfromtheefhandfamilyimportanceofaffinityanddegreeofcrossreactivity
‡A
A Phl p 7-specific IgG4 antibody inhibits allergic patients IgE cross-reactivity to allergens from the EF-hand family: importance of affinity and degree of cross-reactivity
‡9
1
|
|
919
|
|
|
‡a
grasspollenimmunotherapyinducesmucosalandperipheralil10responsesandblockingiggactivity
‡A
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
‡9
1
|
|
919
|
|
|
‡a
toolkitforrapidcloningandexpressionofrecombinantantibodies
‡A
A tool kit for rapid cloning and expression of recombinant antibodies
‡9
1
|
|
919
|
|
|
‡a
allergenspecificityofigg4expressingbcellsinpatientswithgrasspollenallergyundergoingimmunotherapy
‡A
Allergen specificity of IgG4-expressing B cells in patients with grass pollen allergy undergoing immunotherapy
‡9
1
|
|
919
|
|
|
‡a
grasspollenimmunotherapyinducesanallergenspecificiga2antibodyresponseassociatedwithmucosaltgfbetaexpression
‡A
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression
‡9
1
|
|
919
|
|
|
‡a
antibodiesandsuperantibodiesinpatientswithchronicrhinosinusitiswithnasalpolyps
‡A
Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps
‡9
1
|
|
919
|
|
|
‡a
cell2locationmapsfinegrainedcelltypesinspatialtranscriptomics
‡A
Cell2location maps fine-grained cell types in spatial transcriptomics
‡9
1
|
|
919
|
|
|
‡a
epitopespecificitydeterminescrossprotectionofasitinducedigg4antibody
‡A
Epitope specificity determines cross-protection of a SIT-induced IgG4 antibody
‡9
1
|
|
919
|
|
|
‡a
chronicrhinosinusitiswithnasalpolypstargetingigewithantiigeomalizumabtherapy
‡A
Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
‡9
1
|
|
919
|
|
|
‡a
crosstissueimmunecellanalysisrevealstissuespecificadaptationsandclonalarchitectureacrossthehumanbody
‡A
Cross-tissue immune cell analysis reveals tissue-specific adaptations and clonal architecture across the human body
‡9
1
|
|
996
|
|
|
‡2
LC|nb2021001950
|
|
996
|
|
|
‡2
CAOONL|ncf10338312
|
|
996
|
|
|
‡2
ISNI|0000000057907835
|
|
996
|
|
|
‡2
LC|n 86852267
|
|
996
|
|
|
‡2
BLBNB|001573735
|
|
996
|
|
|
‡2
B2Q|0000302110
|
|
996
|
|
|
‡2
ISNI|0000000067660637
|
|
996
|
|
|
‡2
LC|n 2008160350
|
|
996
|
|
|
‡2
LC|n 96114220
|
|
996
|
|
|
‡2
NUKAT|n 2008123710
|
|
996
|
|
|
‡2
ISNI|0000000430505763
|
|
996
|
|
|
‡2
NLA|000059031819
|
|
996
|
|
|
‡2
LC|no2014016160
|
|
996
|
|
|
‡2
ISNI|0000000444681426
|
|
996
|
|
|
‡2
NUKAT|n 2005081309
|
|
996
|
|
|
‡2
ISNI|0000000418428558
|
|
996
|
|
|
‡2
DNB|137206704
|
|
996
|
|
|
‡2
LC|n 80015182
|
|
996
|
|
|
‡2
ISNI|0000000496891310
|
|
996
|
|
|
‡2
ISNI|0000000076840015
|
|
996
|
|
|
‡2
BNF|14851252
|
|
996
|
|
|
‡2
LC|n 2018023429
|
|
996
|
|
|
‡2
BIBSYS|1035350
|
|
996
|
|
|
‡2
BNE|XX6041766
|
|
996
|
|
|
‡2
LC|nb2018012488
|
|
996
|
|
|
‡2
LC|n 84231229
|
|
996
|
|
|
‡2
LC|no2013096040
|
|
996
|
|
|
‡2
LC|n 97872498
|
|
996
|
|
|
‡2
ISNI|0000000025589203
|
|
996
|
|
|
‡2
DNB|134416279
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
